MANGROVE Trial Design

Phase 3

Study Identifier: BGB-3111-306, NCT04002297

Primary Endpoint: IRC-assessed PFS
Key Secondary Endpoints: INV-assessed PFS, ORR, DOR, OS, PROs, safety

Key eligibility criteria

- Previously untreated MCL (N=500)
- Ineligible for stem cell transplant
- ≥70 years old or 60-69 years with comorbidities precluding autologous stem cell transplant
- Measurable disease by CT/MRI
- ECOG PS 0–2
- Adequate marrow/organ function

R 1:1

Treatment

Zanubrutinib 160 mg BID
+ rituximab 375 mg/m² D1
x 6 cycles

→ **Zanubrutinib**
160 mg PO BID
Until unacceptable toxicity or disease progression

Bendamustine 90mg/m² D1-D2
+ rituximab 375 mg/m² D1
x 6 cycles

→ **Observation**

MANGROVE met its primary endpoint of IRC-assessed PFS (HR=0.57; 95% CI, 0.43–0.76; p<0.0001)[4]

1L=first line, BID=twice daily, CT=computed tomography, D=day, DOR=duration of response, ECOG PS=Eastern Cooperative Oncology Group performance status, INV=investigator, IRC=independent review committee,, MCL=mantle cell lymphoma, MRI=magnetic resonance imaging, ORR=objective response rate, OS=overall survival, PFS=progression-free survival, PO=by mouth, PR=partial response, PRO=patient-reported outcome, R=randomized

1. Dreyling M, et al. Future Oncol. 2021;17(3):255-262. 2. Philips T. The Hematologist. 2025;22(5). 3. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04002297. Accessed 10Apr26. 4. https://ir.beonemedicines.com/news/beone-medicines-announces-positive-phase-3-results-for-brukinsa-in-frontline-mantle-cell-lymphoma/44597eac-a44b-451f-a021-48d345cdb85e. Accessed 06July26.